EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Design, Synthesis, and Evaluation of Bis ‐Chalcones and Bis ‐Flavones as Selective COX ‐2 Inhibitors

Rui Pereira, Marisa Freitas, Alberto N Araújo, Vera L M Silva iD, Eduarda Fernandes iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70268 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2026. Written by Rui Pereira and 4 co-authors. Institution: LAQV-REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. Major MEDLINE topics: Chalcones, Cyclooxygenase 2 Inhibitors, Drug Design, Cyclooxygenase 2. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Fundação para a Ciência e a Tecnologia.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Over the past two decades, the search for safe and effective COX‐2 inhibitors has spurred extensive research on flavonoids. Within this context, synthetic flavonoid dimers have emerged as a promising subclass with potential anti‐inflammatory activity. To investigate whether dimerization enhances their potency and selectivity, novel A‐fused bis ‐chalcones and A‐fused bis ‐flavones were synthesized and evaluated for their inhibitory activity against isolated human COX‐1 and COX‐2 enzymes, as well as their effects on prostaglandin E 2 production in whole human blood. Interestingly, the most active compound identified was a monomeric chalcone sharing the same substitution pattern as the top‐performing bis ‐chalcone, suggesting that key structural features drive activity regardless of dimerization. While the dimeric nature of bis ‐chalcones did not enhance COX‐2 inhibition or selectivity in this study, these results provide valuable insights into structure–activity relationships. Furthermore, all active compounds against the isolated enzyme showed reduced potency in whole blood, possibly due to plasma protein binding limiting bioavailability. This study highlights the importance of rational design for further development of dimeric flavonoids, in particular strategies aimed at optimizing bioavailability.

Subjects

MeSH terms (MEDLINE)

ChalconesCyclooxygenase 2 InhibitorsDrug DesignCyclooxygenase 2FlavonesHumansStructure-Activity RelationshipCyclooxygenase 1DinoprostoneDimerization

Author keywords

bis‐chalconesbis‐flavonescyclooxygenase‐2enzyme inhibitionin vitro evaluationsynthesiswhole‐blood

Substances

ChalconesCyclooxygenase 2 InhibitorsCyclooxygenase 2FlavonesCyclooxygenase 1Dinoprostone

Authors and institutions

  • LAQV-REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal.

ORCID profiles: Vera L M Silva, Eduarda Fernandes

Funding

  • Fundação para a Ciência e a Tecnologia

Cite

APA

Pereira, R., Freitas, M., Araújo, A. N., Silva, V. L. M., & Fernandes, E. (2026). Design, Synthesis, and Evaluation of Bis ‐Chalcones and Bis ‐Flavones as Selective COX ‐2 Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70268

Vancouver

Pereira R, Freitas M, Araújo AN, Silva VLM, Fernandes E. Design, Synthesis, and Evaluation of Bis ‐Chalcones and Bis ‐Flavones as Selective COX ‐2 Inhibitors. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70268

BibTeX
@article{Pereira2026,
  author = {Pereira, Rui and Freitas, Marisa and Araújo, Alberto N and Silva, Vera L M and Fernandes, Eduarda},
  title = {Design, Synthesis, and Evaluation of Bis ‐Chalcones and Bis ‐Flavones as Selective COX ‐2 Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70268}
}
Start for free →